BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Healthtrust
Queensland Health
Accenture
Deloitte
Teva
Dow
Moodys
QuintilesIMS
Baxter

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,357,394

« Back to Dashboard

Which drugs does patent 8,357,394 protect, and when does it expire?

Patent 8,357,394 protects MOXATAG and is included in one NDA.

This patent has eleven patent family members in six countries.
Summary for Patent: 8,357,394
Title:Compositions and methods for improved efficacy of penicillin-type antibiotics
Abstract: Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide T>MIC.sub.90 in the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's MIC.sub.90, while providing a total dosage of the penicillin-type antibiotic for a 24-hour dosing interval.
Inventor(s): Flanner; Henry H. (Montgomery Village, MD), Guttendorf; Robert J. (Gaitherburg, MD), Clausen; Susan P. (Ijamsville, MD), Treacy; Donald (Woodbine, MD), Burnside; Beth A. (Bethesda, MD)
Assignee: Shionogi Inc. (Florham Park, NJ)
Application Number:11/636,291
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Drugs Protected by US Patent 8,357,394

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vernalis R And D Ltd MOXATAG amoxicillin TABLET, EXTENDED RELEASE;ORAL 050813-001 Jan 23, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,357,394

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,299,052 Pharmaceutical compositions and methods for improved bacterial eradication ➤ Subscribe
8,778,924 Modified release amoxicillin products ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,357,394

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 5788142 ➤ Subscribe
Japan 2010511607 ➤ Subscribe
European Patent Office 1969134 ➤ Subscribe
European Patent Office 1968586 ➤ Subscribe
China 101563466 ➤ Subscribe
Canada 2635606 ➤ Subscribe
Canada 2635378 ➤ Subscribe
Australia 2006351475 ➤ Subscribe
Australia 2006321782 ➤ Subscribe
World Intellectual Property Organization (WIPO) 2007067770 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Argus Health
Chubb
Fish and Richardson
Fuji
Harvard Business School
Daiichi Sankyo
UBS
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot